参考資料5:基礎論文

番号 論文名

1 An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.
Bischoff JR, Kirn DH, Williams A, et al. Science. 1996 Oct 18;274(5286):373-6.

2 ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Heise C, Sampson-Johannes A, Williams A, et al. Nat Med. 1997 Jun;3(6):639-45.

3 p53-dependent cell death/apoptosis is required for a productive adenovirus infection.
Hall AR, Dix BR, O'Carroll SJ, et al. Nat Med. 1998 Sep;4(9):1068-72.

4 Promising new agents for treatment of patients with colorectal cancer.
Von Hoff DD. Semin Oncol. 1998 Oct;25(5 Suppl 11):47-52.

5 ONYX-015: clinical data are encouraging.
Kirn D, Hermiston T, McCormick F. Nat Med. 1998 Dec;4(12):1341-2.

6 Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy.
Heise CC, Williams AM, Xue S, et al. Cancer Res. 1999 Jun 1;59(11):2623-8.

7 Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects.
Heise CC, Williams A, Olesch J, Kirn DH. Cancer Gene Ther. 1999 Nov-Dec;6(6):499-504.

8 Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status.
Heise C, Ganly I, Kim YT, et al. Gene Ther. 2000 Nov;7(22):1925-9.

9 ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients.
You L, Yang CT, Jablons DM. Cancer Res. 2000 Feb 15;60(4):1009-13.

10 In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.
Rogulski KR, Freytag SO, Zhang K, et al. Cancer Res. 2000 Mar 1;60(5):1193-6.

11 ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus.
Ries S, Korn WM. Br J Cancer. 2002 Jan 7;86(1):5-11.

12 ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines.
Portella G, Scala S, Vitagliano D, et al. J Clin Endocrinol Metab. 2002 Jun;87(6):2525-31.

13 Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants.
Wadler S, Yu B, Tan JY, et al. Clin Cancer Res. 2003 Jan;9(1):33-43.

14 Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts.
Geoerger B, Grill J, Opolon P, et al. Br J Cancer. 2003 Aug 4;89(3):577-84.

15 ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells.
Portella G, Pacelli R, Libertini S, et al. J Clin Endocrinol Metab. 2003 Oct;88(10):5027-32.

16 An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.
Rudin CM, Cohen EE, Papadimitrakopoulou VA, et al. B1J Clin Oncol. 2003 Dec 15;21(24):4546-52.

17 Combination of Targeting Gene-ViroTherapy with 5-FU enhances antitumor efficacy in malignant colorectal carcinoma.
Qiu S, Ruan H, Pei Z, et al. J Interferon Cytokine Res. 2004 Apr;24(4):219-30.

18 The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma.
Morley S, MacDonald G, Kirn D, et al. Clin Cancer Res. 2004 Jul 1;10(13):4357-62.

19 Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin.
Reid TR, Freeman S, Post L, et al. Cancer Gene Ther. 2005 Aug;12(8):673-81.

20 China approves world's first oncolytic virus therapy for cancer treatment.
Garber K. J Natl Cancer Inst. 2006 Mar 1;98(5):298-300.

21 The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck.
Norris JS, Norris KL, Holman DH, et al. Future Oncol. 2005 Feb;1(1):115-23.

22 p53 as a target for anti-cancer drug development.
Bouchet BP, de Fromentel CC, Puisieux A, et al. Crit Rev Oncol Hematol. 2006 Jun;58(3):190-207.

23 Model-driven approaches for in vitro combination therapy using ONYX-015 replicating oncolytic adenovirus.
Zurakowski R, Wodarz D. J Theor Biol. 2007 Mar 7;245(1):1-8.

24 Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver.
Au T, Thorne S, Korn WM, et al. Cancer Gene Ther. 2007 Feb;14(2):139-50.

25 Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas.
Jiang H, Gomez-Manzano C, Lang FF, et al. J. Curr Gene Ther. 2009 Oct;9(5):422-7.